Schizophrenia Clinical Trials in Los Angeles, California

7 studies are recruiting for schizophrenia in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Los Angeles, California

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

2. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0153, Los Angeles, California

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

3. Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

   The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other …

   Stage

   Not phased

   Ages

   18 to 45

   Site

   UCLA Aftercare Research Program, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT05890183 on ClinicalTrials.gov

4. Tolerability of MDMA in Schizophrenia

   Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to signific…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   UCLA, Los Angeles, California

   Run by

   Anya Bershad, MD, PhD

   See if you can join NCT05770375 on ClinicalTrials.gov

5. Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

   Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   7 in total

   Run by

   New York State Psychiatric Institute

   See if you can join NCT05208190 on ClinicalTrials.gov

6. Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

   Low social motivation is a significant symptom of schizophrenia and is a major cause of disability and suffering for many patients struggling with the illness. Social motivation refers to the drive to participate in or abstain from social activities. Many patients with schizophrenia evidence both d…

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   UCLA Semel Institute, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT05778591 on ClinicalTrials.gov

7. Study of ALTO-101 in Patients With Schizophrenia

   This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

   Stage

   Phase 2

   Ages

   21 to 55

   Site

   Site 5063, Los Angeles, California

   Locations

   14 in total

   Run by

   Alto Neuroscience

   See if you can join NCT06502964 on ClinicalTrials.gov